Kala Pharmaceuticals (KALA, $22.34 ) Q4 earnings miss estimates
Kala Pharmaceuticals (KALA) recently reported its fourth-quarter earnings, which missed estimates, causing some concern among investors. The company reported a loss of $0.32 per share, missing the consensus estimate of a loss of $0.29 per share. Despite the miss, the company's revenue beat expectations, coming in at $14.6 million compared to the expected $13.8 million.
The Q4 earnings miss is certainly a cause for concern, but it's important to consider the larger picture when evaluating KALA as an investment opportunity. One positive sign for the company is the recent crossover of its 50-day moving average above its 200-day moving average on February 17, 2023. This technical indicator, known as a "golden cross," is a bullish signal that suggests the stock is shifting to an upward trend.
Moving averages are commonly used by technical analysts to identify trends and potential buy/sell signals. The 50-day moving average is a short-term trend indicator, while the 200-day moving average is a long-term trend indicator. When the 50-day moving average crosses above the 200-day moving average, it suggests that the stock is gaining momentum and could continue to rise in the future.
Overall, Kala Pharmaceuticals' Q4 earnings miss is undoubtedly noteworthy, but it's crucial to consider more than just one quarter's worth of data. Recent golden crosses for the company are possibly bullish signs that might point to a longer-term higher trend for the stock.
KALA sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for KALA moved above the 200-day moving average on December 26, 2024. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on December 26, 2024. You may want to consider a long position or call options on KALA as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for KALA just turned positive on December 26, 2024. Looking at past instances where KALA's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
KALA moved above its 50-day moving average on December 26, 2024 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for KALA crossed bullishly above the 50-day moving average on January 03, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where KALA advanced for three days, in of 212 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for KALA moved out of overbought territory on January 06, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 44 cases where KALA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
KALA broke above its upper Bollinger Band on January 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KALA entered a downward trend on December 24, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. KALA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.606) is normal, around the industry mean (15.212). P/E Ratio (0.000) is within average values for comparable stocks, (87.972). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.839). KALA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (258.672).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KALA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a developer of ophthalmic treatments based on its mucosal penetrating product platform
Industry Biotechnology